Anlotinib suppresses homologous recombination via the E2F8-RAD51 axis to activate STING immunity and potentiate PARP inhibitor synthetic lethality in resistant small cell lung cancer
Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy that almost invariably acquires resistance to first-line platinum-based chemotherapy, leading to early relapse. PARP inhibitors (PARPi) hold theoretical potential for SCLC due to universal TP53/RB1 deletion, but their monotherapy activity has...